Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

GBIL Pays $29 Million to Acquire Surgical Robot for China from TransEnterix

publication date: Dec 18, 2017

Great Belief International Limited, a BVI investment company, will pay $29 million to acquire SurgiBot, a minimally invasive surgical robot, from TransEnterix of North Carolina. GBIL will manufacture the system in China and work to obtain CFDA approval of SurgiBot. It plans to commercialize the system in China through a Sinopharm subsidiary, while TransEnterix will retain rights to co-promote SurgiBot outside of China. SurgiBot, which has not been approved in any country, is a single-port, robotically enhanced laparoscopic platform for abdominal surgeries. More details....

Stock Symbol: (NYSE: TRXC)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.